Absorbable suture thread Premisut PGLA-910

general surgeryophthalmic surgerysoft tissue surgery

Overview
Premisut PGLA-910 suture (Polyglactin 910) is a sterile synthetic multifilament braided absorbable surgical suture made from a co-polymer of 90% glycolide and 10% L-lactide. Available dyed with D&C Violet No. 2 (in compliance with U.S. Code of Federal Regulations) or undyed. For lubrication and smooth tissue passage, the suture is coated with a blend of Polyglactin 370 co-polymer (30% glycolide, 70% lactide) and calcium stearate.

Intended use
Premisut PGLA-910 is intended for general soft tissue approximation and ligation, including ophthalmic procedures. Not intended for use in cardiovascular or neurological procedures.

Absorption and tissue reaction
After implantation the suture provokes a minimal initial inflammatory response and is gradually replaced by ingrowth of fibrous connective tissue. The absorbable suture is degraded by hydrolysis into glycolic and lactic acids, which are metabolized by the body, resulting in progressive loss of tensile strength followed by mass loss.

Note
Technical characteristics (coating, tensile strength, needle composition, packaging, etc.) may vary by market and can be adjusted to meet local requirements.

Technical specifications

• Composition: Polyglactin 910 co-polymer — 90% glycolide, 10% L-lactide.
• Coating: Polyglactin 370 co-polymer (30% glycolide, 70% lactide) with calcium stearate for lubrication and smooth passage.
• Dye: D&C Violet No. 2 (complies with U.S. Code of Federal Regulations); undyed option available.
• Structure: Sterile, synthetic, multifilament braided absorbable surgical suture.
• Indications: General soft tissue approximation and ligation; suitable for ophthalmic procedures.
• Contraindications/limitations: Not for use in cardiovascular or neurological procedures.
• Absorption mechanism: Hydrolysis to glycolic and lactic acids; progressive loss of tensile strength followed by mass loss.
• Tissue response: Minimal initial inflammatory reaction; eventual replacement by fibrous connective tissue.
• Market variations: Coating, tensile strength, needle composition and packaging may differ by market.